UPDATE 1-Higher heart risk seen with Abbott dissolving stent after 2 years -study

WASHINGTON, March 18 (Reuters) - Patients who received Abbott Laboratories' novel dissolving vascular stent had a significantly higher rate of serious adverse heart events than those treated with the company's widely used Xience drug-coated metal stent two years after implantation, according to data presented on Saturday.